Blackstone (BX) is exploring the sale of Anthos Therapeutics, a developer of a new generation of blood thinners it launched four years ago with backing from Novartis (NVS), according to people familiar with the matter, Reuters’ David Carnevali says. Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250M that Blackstone invested when it founded Anthos in 2019, the sources said. The company’s anticoagulants have made significant progress in late-stage clinical trials, the sources added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BX:
- Rover Group to be acquired by Blackstone for $11.00 per share in cash
- BofA expects KKR and Apollo Global to be added to S&P 500 over next 6 months
- Blackstone to acquire Civica, terms not disclosed.
- Blackstone in advanced talks over $2.5B deal for Civica, WSJ reports
- eBay announces support for offer led by Permira, Blackstone to acquire Adevinta